EarningsQ2 2026 Earnings Report
MX:MIRM Q2 2026 EPS Results
Actual EPS-$19.25
Consensus EPS-$13.49
Beat/MissMissed by -$5.76
One Year Ago EPS-$2.18
MX:MIRM Q2 2026 Revenue Results
Actual Revenue$3.20B
Expected Revenue$3.02B
Beat/MissBeat by +$180.05M
YoY Revenue Growth+37.92%
Earnings Announcement Details
QuarterQ2 2026
Date08/05/2026
TimeAfter Close
Conference CallWednesday, August 5, 2026
MX:MIRM Upcoming Earnings
Mirum Pharmaceuticals's next earnings date is estimated for November 17, 2026, based on past reporting schedules.
Q2 2026 Earnings Call Audio
MX:MIRM Q2 2026 Earnings Call
0:00 / 0:00
Q2 2026 Earnings Slide Deck
No slide deck is available for this earnings event.
Q2 2026 Earnings Call Summary
Earnings Call Sentiment|Positive
The call presented strong commercial execution (Q2 sales up 37.5% YoY), improved margins (+~5 percentage points) a fortified balance sheet (cash up ~43.5%, successful convertible note financing), and multiple near-term clinical and regulatory catalysts (Zilurgisertib PDUFA, volovitug/volixibat and volovitug AZURE readouts). The most significant negative item is regulatory uncertainty for volixibat in PSC after the FDA recommended a Phase 3, leading to an NDA timing delay to H1 2027 and added execution risk. Overall, positive commercial and financial momentum and multiple upcoming catalysts outweigh the regulatory setback, but the PSC pathway remains a material watch item.Company Guidance
Strong Quarterly Revenue Growth
Net product sales of $176.0M in Q2 2026, up from $128.0M in Q2 2025 (+37.5% YoY), driven by portfolio demand and commercial execution.
Raised Full-Year Guidance
Increased 2026 net product sales guidance to $680M–$700M based on strong Q2 performance and sustained demand across the portfolio.
Product-Level Strength — Livmarli and Bile Acid Medicines
Livmarli net product sales of $129M in Q2 (U.S. $92M; international $37M). Bile acid medicines contributed roughly $48M for the quarter; adult PFIC diagnosis and expanding international reimbursement cited as growth drivers.
Robust Balance Sheet and Cash Position
Cash, cash equivalents and investments of $561M as of June 30, 2026 (up from $391M at start of year, +~43.5%). Issued $690M aggregate principal 0% convertible notes (net proceeds $672M) and settled 75% of 2029 notes, adding $197M cash and reducing interest expense; operating cash flow was positive in Q2.
Improved Commercial Margin
Commercial cash contribution margin in the high-50s percent in H1 2026, approximately a 5 percentage-point improvement vs prior year.
Pipeline Progress and Near-Term Milestones
Multiple near-term catalysts: Zilurgisertib (FOP) has a September PDUFA with potential U.S. launch in Q4 and an EU filing submitted; volovitug (AZURE-1 top-line later this quarter, AZURE-4 in Q4) on track for a potential BLA in H1 2027; EXPAND (Livmarli additional cholestatic indications) top-line expected Q4 with potential sNDA next year; MRN-338 proof-of-concept in fragile X expected next year.
Regulatory Recognition for Volixibat in PSC
VISTAS met its primary endpoint in cholestatic pruritus due to PSC and FDA granted Breakthrough Therapy designation, acknowledging potential to address an unmet need.
MX:MIRM Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed